Johnson & Johnson (NYSE:JNJ) Shares Bought by one8zero8 LLC

by · The Cerbat Gem

one8zero8 LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,079 shares of the company’s stock after buying an additional 1,416 shares during the quarter. Johnson & Johnson makes up 2.7% of one8zero8 LLC’s holdings, making the stock its 7th biggest holding. one8zero8 LLC’s holdings in Johnson & Johnson were worth $11,622,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. MBA Advisors LLC grew its position in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its holdings in shares of Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after purchasing an additional 69 shares during the last quarter. Nabity Jensen Investment Management Inc increased its stake in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after buying an additional 69 shares during the period. Jackson Grant Investment Advisers Inc. raised its holdings in Johnson & Johnson by 0.5% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 12,970 shares of the company’s stock valued at $2,151,000 after buying an additional 69 shares during the last quarter. Finally, Almanack Investment Partners LLC. boosted its position in Johnson & Johnson by 1.1% during the 1st quarter. Almanack Investment Partners LLC. now owns 6,633 shares of the company’s stock worth $1,100,000 after buying an additional 71 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on JNJ shares. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Barclays increased their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $174.50.

Read Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $168.29 on Friday. The firm has a market capitalization of $404.92 billion, a P/E ratio of 18.00, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a fifty day moving average of $156.08 and a 200-day moving average of $155.88. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.82 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.09%. Johnson & Johnson’s payout ratio is currently 55.61%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).